Key result
mRNA COVID-19 vaccination is linked to myocarditis in ~1 in 30,000 second doses among young males.
Why the study?
Although myocarditis/pericarditis cases after primary mRNA COVID-19 vaccination have been reported, less was known about the incidence following booster doses.
What is the incidence of myocarditis/pericarditis following mRNA COVID-19 vaccination in persons aged 5 to 39 years?
Observational (n=12,500,000)
Yes
What is the incidence of myocarditis/pericarditis following mRNA COVID-19 vaccination in persons aged 5 to 39 years?
The incidence of myocarditis/pericarditis after mRNA COVID-19 vaccination is highest among male adolescents after the second dose and first booster, though overall rates remain rare.
No takes yet. Share an insight, caveat, or question.
Rare incidence in young males supports surveillance; leaves open risk-benefit optimization in low-risk groups.
Goddard et al. (2022) conducted an observational in Myocarditis/Pericarditis (n=12,500,000). mRNA COVID-19 vaccination was evaluated on Incidence of myocarditis/pericarditis 0 to 7 days after vaccination. mRNA COVID-19 vaccination in persons aged 5-39 years resulted in myocarditis/pericarditis in approximately 1 in 30,000 second doses and 1 in 50,000 first boosters, disproportionately affecting males.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: